Recent Updates
Recently added Catalysts
REGN

New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma

Monday, May 21, 2018 1 min read
Key Takeaway: New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma

Full Press Release Details

New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma.
Tags: REGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 21, 2018